Valuation : Nectar Lifesciences Limited

Market Cap 2.34B 24.79M 21.32M 20.05M 18.31M 34.24M 34.35M 238M 91.91M 1.2B 93.11M 91.07M 3.82B P/E 2025
-4.53x
P/E 2026 -0.69x
Enterprise Value 1.09B 11.56M 9.95M 9.35M 8.54M 15.97M 16.02M 111M 42.87M 560M 43.43M 42.48M 1.78B EV / Sales 2025
0.64x
EV / Sales 2026 -
Free-Float
44.34%
Yield 2025 *
-
Yield 2026 -
08-15 Nectar Lifesciences Limited Changes Its Corporate Office in Chandigarh CI
08-14 Nectar Lifesciences Limited Announces Board and Committee Changes, Effective August 14, 2026 CI
08-14 Nectar Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
08-06 Nectar Lifesciences Limited Announces Resignation of Dr. Surulichamy Senthilkumar from Non-Executive Non-Independent Director, Effective August 06, 2026 CI
07-11 Nectar Lifesciences Limited Announces Change in Registered Office Address CI
05-30 Nectar Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
03-05 Nectar Lifesciences Limited completed the acquisition of Avensis Exports Private Limited. CI
03-02 Nectar Lifesciences to acquire 100% paid-up equity share capital of Avensis Exports RE
03-01 Nectar Lifesciences Limited agreed to acquire Avensis Exports Private Limited for INR 2.5 million. CI
01-23 Nectar Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-15 Tranche Update on Nectar Lifesciences Limited's Equity Buyback Plan announced on December 3, 2025. CI
01-05 Nectar Lifesciences Limited's Equity Buyback announced on May 6, 2023, has closed with 30,000,000 shares, representing 13.38% for INR 810 million. CI
12-19 Capnest Health Care Private Limited entered into Business Transfer agreement to acquire Empty Hard Gelatin Capsule unit at Bhatoli from Nectar Lifesciences Limited for approximately INR 200 million. CI
1 day+1.97%
1 week+2.48%
Current month-0.72%
1 month+17.31%
3 months+7.27%
6 months+9.54%
Current year-36.41%
1 week 11.71
Extreme 11.71
12.72
1 month 10.16
Extreme 10.16
13.4
Current year 9.2
Extreme 9.2
20.94
1 year 9.2
Extreme 9.2
22.49
3 years 9.2
Extreme 9.2
56.39
5 years 9.2
Extreme 9.2
56.39
10 years 7.2
Extreme 7.2
56.39
Manager TitleAgeSince
Director of Finance/CFO 68 13/11/2022
Compliance Officer - 31/03/2025
Director TitleAgeSince
Chairman 66 26/06/1995
Director/Board Member 69 10/02/2019
Director/Board Member 75 20/09/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%+2.48% - - 25.08M
-0.44%-2.26%+19.26%+66.79% 48.26B
+0.60%-4.76%+39.20%+117.99% 40.5B
-0.40%-2.37%-9.86%+11.63% 11.85B
-0.60%-1.46%+13.97%+83.19% 11.83B
-1.50%-0.38%+24.76%+138.18% 9.36B
-0.86%-3.20%+23.76%+38.38% 7.5B
+0.04%-2.64%+36.22%-13.57% 7.37B
-0.12%-0.84%+19.39%+215.34% 7.28B
-0.32%-1.85%-46.31%+22.01% 5.19B
Average -0.16%-2.35%+13.38%+75.55% 16.57B
Weighted average by Cap. -0.22%-1.85%+21.08%+82.39%

Financials

2025 2026
Net sales 16.7B 177M 152M 143M 130M 244M 245M 1.69B 655M 8.55B 663M 649M 27.25B -
Net income -1.14B -12.02M -10.34M -9.72M -8.88M -16.6M -16.65M -115M -44.56M -582M -45.14M -44.15M -1.85B -2.93B -30.97M -26.63M -25.05M -22.87M -42.77M -42.91M -297M -115M -1.5B -116M -114M -4.78B
Net Debt 5.62B 59.45M 51.13M 48.09M 43.9M 82.1M 82.37M 570M 220M 2.88B 223M 218M 9.17B -1.25B -13.23M -11.38M -10.7M -9.77M -18.27M -18.33M -127M -49.04M -641M -49.68M -48.59M -2.04B
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
111
Date Price Change Volume
08/09/26 12.40 +1.97% 5,073
07/09/26 ₹12.16 -0.49% 19,641
04/09/26 ₹12.22 +0.58% 15,096
03/09/26 ₹12.15 -0.98% 9,226
02/09/26 ₹12.27 +1.40% 25,472
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!